Garrett M. Nash, MD, MPH, FACS, FASCRS
Dr. Garrett M. Nash is a surgical oncologist with specialized training in surgical techniques for the management of various cancers, including peritoneal surface malignancies like peritoneal mesothelioma. He uses minimally invasive techniques including laparoscopy, single-incision laparoscopy, and robotic surgery.[1]
Dr. Nash has significant expertise in the use of the complex procedure known as cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of malignant peritoneal mesothelioma. He is the primary investigator for a trial assessing the benefits of its use for the treatment of metastatic appendiceal and colorectal cancer.
Education and Career
Dr. Nash attended medical school and earned his medical degree from Columbia University. He completed surgical residencies at the University of Massachusetts Medical School and at New York Presbyterian/Weill Cornell Medical College and completed a fellowship in Colon and Rectal Surgery at New York Presbyterian as well as a fellowship in Colorectal Oncology at Memorial Sloan Kettering Cancer Center.[1]
Board-certified in both Surgery and Colon and Rectal Surgery, Dr. Nash also earned a Master’s in Public Health from Harvard’s T.H. Chan School of Public Health. At Memorial Sloan Kettering Cancer Center, he holds the title of Vice Chair for Quality and Safety in the Department of Surgery.
Dr. Nash runs NYC marathons and half marathons each year for Fred’s Team to raise money to support cancer research at Memorial Sloan Kettering and has raised over $75,000 over eleven races. He is the author of many papers on subjects ranging from cytoreductive surgery and intraperitoneal chemotherapy to mechanisms of tumor progression and minimally invasive surgery.
Research
In addition to his work on the ICARuS Trial (Intraperitonetoneal Chemotherapy After cytoReducuive Surgery), Dr. Nash is actively engaged in research involving clinical trials of new technology and surgical techniques for advanced malignancies. He is also interested in optimizing surgical margins and lymph node retrieval.[1]
Dr. Nash’s active clinical trials include:
- A Phase 2 Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
- ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Phase II Study of Early Post-Operative Abdominal Chemotherapy versus Heated Abdominal Chemotherapy for Cancers of the Appendix, Colon, or Rectum that Have Spread to the Abdominal Lining
The following articles are among Dr. Nash’s notable articles:
- Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma.
Melina E Marmarelis, Xiao Wang, Leonid Roshkovan, Connor B Grady, John T Miura, Michelle S Ginsberg, Christine A Ciunci, Jacklynn Egger, Suzanne Walker, Andrea Cercek,…>; JAMA Network Open. 2023 Mar 1
- Development of Memorial Sloan Kettering (MSK) surgery stress score for older adults with cancer.10.1200/JCO.2022.40.16_suppl.e24014, Journal of Clinical Oncology.
- Clinical activity of pembrolizumab monotherapy in diffuse malignant peritoneal mesothelioma. Wang, Xiao & Offin, Michael & Roshkovan, Leonid & Miura, John & Ginsberg, Michelle & Ciunci, Christine & Egger, Jacklynn & Walker, Suzanne & Cercek, Andrea & Litzky, Leslie & Nash, Garrett & Haas, Andrew & Karakousis, Giorgos & Cengel, Keith & Katz, Sharyn & Zauderer, Marjorie & Langer, Corey & Marmarelis, Melina. (2022). Journal of Clinical Oncology. 40. 8557-8557. 10.1200/JCO.2022.40.16_suppl.8557.
